Alliancebernstein L.P. Buys 197,778 Shares of Repligen Corporation $RGEN

Alliancebernstein L.P. boosted its stake in shares of Repligen Corporation (NASDAQ:RGEN) by 21.8% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,104,171 shares of the biotechnology company’s stock after acquiring an additional 197,778 shares during the quarter. Alliancebernstein L.P. owned 1.96% of Repligen worth $147,595,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of RGEN. AQR Capital Management LLC purchased a new stake in shares of Repligen during the first quarter valued at approximately $262,000. Jones Financial Companies Lllp raised its holdings in Repligen by 3,850.6% during the 1st quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock valued at $814,000 after buying an additional 6,238 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in Repligen by 16.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock valued at $18,067,000 after buying an additional 20,375 shares during the last quarter. ProShare Advisors LLC boosted its position in Repligen by 4.3% during the 2nd quarter. ProShare Advisors LLC now owns 2,316 shares of the biotechnology company’s stock valued at $288,000 after buying an additional 96 shares during the period. Finally, Intech Investment Management LLC purchased a new stake in Repligen during the 2nd quarter valued at $1,435,000. 97.64% of the stock is currently owned by institutional investors.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $115.11 on Tuesday. Repligen Corporation has a 1 year low of $102.96 and a 1 year high of $175.77. The stock has a market capitalization of $6.48 billion, a P/E ratio of 135.42, a P/E/G ratio of 2.23 and a beta of 1.14. The company’s 50-day moving average is $144.34 and its 200 day moving average is $147.00. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.37 and a quick ratio of 7.12.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.44 by $0.05. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The business had revenue of $197.91 million during the quarter, compared to analyst estimates of $192.23 million. During the same period last year, the business posted $0.44 earnings per share. Repligen’s quarterly revenue was up 18.1% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. On average, sell-side analysts expect that Repligen Corporation will post 1.72 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on RGEN shares. KeyCorp reaffirmed an “overweight” rating on shares of Repligen in a research note on Wednesday, February 25th. UBS Group cut their target price on Repligen from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Wells Fargo & Company reduced their price target on Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Barclays dropped their price objective on Repligen from $200.00 to $175.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. Finally, Weiss Ratings lowered Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Tuesday, March 3rd. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and a consensus target price of $174.58.

Insider Activity at Repligen

In related news, Director Karen A. Dawes sold 275 shares of Repligen stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $161.00, for a total transaction of $44,275.00. Following the sale, the director directly owned 91,821 shares in the company, valued at $14,783,181. The trade was a 0.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.20% of the stock is currently owned by insiders.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.